Shen, Jianyu
Guillén Mancina, Emilio
Chen, Shenyu
Manolakou, Theodora http://orcid.org/0000-0001-5284-6655
Gad, Helge
Warpman Berglund, Ulrika
Sanjiv, Kumar
Helleday, Thomas http://orcid.org/0000-0002-7384-092X
Funding for this research was provided by:
Barncancerfonden (2021-0030)
Vetenskapsrådet (2015-00162)
Cancerfonden (21-1490)
Radiumhemmets Forskningsfonder
The Swedish Innovation agency, Formas
China Sponsorship Council
'Margarita Salas' grants, funded by the Spanish Recovery, Transformation and Resilience Plan and Next Generation EU
David och Astrid Hageléns Stiftelse
Helleday Foundation
Article History
Received: 20 December 2023
Revised: 7 May 2024
Accepted: 10 May 2024
First Online: 25 May 2024
Competing interests
: Oxcia AB develops TH1579 (OXC-101) commercially and U.W.B is CEO of Oxcia AB. T.H., H.G., K.S., and U.W.B. have shares in Oxcia AB. The other authors declare that there are no conflicts of interest.